MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

EQS-News: MorphoSys AG


/ Key word: Miscellaneous





MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023

Related Keywords

United States ,Orlando ,Florida ,Massachusetts ,University Hospital ,Boston ,Planegg ,Bayern ,Germany ,Canada ,Delaware ,American ,Steven Stein ,Tim Demuth ,Johannes Duell ,American Association For Cancer Research Annual Meeting ,Nasdaq ,Morphosys Us Inc ,Exchange Commission ,Xencor Inc ,Practice Research Clinical Haematology ,American Association For Cancer Research ,Twitter ,Drug Administration ,Linkedin ,Incyte Announce Five Year Results ,Showed Prolonged ,Durable Responses ,American Association ,Cancer Research Annual Meeting ,Cancer Research ,Annual Meeting ,Medical Clinic ,Chief Research ,Development Officer ,Chief Medical Officer ,Diffuse Largeb Cell Lymphoma ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,Morphosy Annual Report ,Practice Research ,Morphosys Ag Stock Exchange ,News ,Information ,Press Release ,Morphosys ,Key ,End ,Incyte ,Nnounce ,Results ,F ,Study ,Howed ,Durable ,Responses ,N ,Relapsed ,Dr ,Efractory Mor De0006632003 ,